var data={"title":"Tamsulosin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tamsulosin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7010?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tamsulosin-drug-information\" class=\"drug drug_general\">see &quot;Tamsulosin: Drug information&quot;</a> and <a href=\"topic.htm?path=tamsulosin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tamsulosin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224754\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Flomax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224755\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flomax CR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1037398\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alpha<sub>1</sub> Blocker</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1037429\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tamsulosin-drug-information\" class=\"drug drug_general\">see &quot;Tamsulosin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nephrolithiasis, distal stones:</b> Limited data available; optimal dose not established (Mokhless 2012; Tasian 2014):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 4 years: Oral: 0.2 or 0.4 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &gt;4 years and Adolescents: Oral: 0.4 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on two studies. The larger was a multi-institutional retrospective cohort study of pediatric patients with stones up to 10 mm; patients received either tamsulosin 0.4 mg once daily (n=99, median age: 14.8 years) or analgesics alone (n=175). Spontaneous stone passage was higher in the treatment group (55% vs 44%, p=0.03); treatment group was older and had smaller, more distal stones. When adjusted for stone size and location as part of analysis of 99 case matched pairs, success was also higher in the treatment group (OR 3.31, 95% CI: 1.49 to 7.34) (Tasian 2014). The smaller study was a prospective, randomized controlled trial of pediatric patients with stones up to 12 mm; patients received either tamsulosin 0.4 mg once daily (0.2 mg if &le;4 years old) (n=33, age: 2 to 15 years) or placebo (n=28). In this study, 45% of the treatment group had previously received either extracorporeal shock wave lithotripsy (ESWL) or percutaneous nephrolithotomy, but none in the control group had received these therapies; however, stone size at the start of treatment was similar between groups. Treatment resulted in higher expulsion rate (87.8% vs 64.2%, p&lt;0.01), less days to expulsion (mean: 8.2 vs 14.5 days, p&lt;0.001), less pain episodes (mean: 1.4 vs 2.2, p&lt;0.02) and less need for analgesia (mean: 0.7 vs 1.4, p&lt;0.02) (Mokhless 2012). In both studies, tamsulosin was well tolerated and there were no reported adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary bladder neck dysfunction:</b> Limited data available: Children &ge;3 years and Adolescents: Oral: Initial dose: 0.2 mg once daily, increase by 0.2 mg increments based on response (symptoms and urodynamic studies) and tolerability. Mean effective dose: 0.4 mg daily; maximum reported daily dose: 0.8 mg/<b>day</b>. Dosing based on two trials evaluating treatment with alpha blockers, including over 50 pediatric patients who received tamsulosin. Treatment resulted in improved urine flow rates and decreased post-void residual urine volume; values returned to pretreatment levels when therapy was discontinued. Tamsulosin was well tolerated with no major adverse effects and benefits continued for at least 3 years (Donohoe 2005; Van Batavia 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Benign prostatic hyperplasia (BPH):</b> Males: Oral: 0.4 mg once daily ~30 minutes after the same meal each day; dose may be increased after 2 to 4 weeks to 0.8 mg once daily in patients who fail to respond. If therapy is discontinued or interrupted for several days, restart with 0.4 mg once daily. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adult males: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;10 mL/minute: No adjustment needed </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adult males:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224732\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Flomax: 0.4 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224719\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1037434\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Per the manufacturer, capsules should be swallowed whole; do not crush, chew, or open. In pediatric trials, capsules were opened and the contents mixed with food (eg, yogurt or pudding) or juice (Donohoe 2005; Tasian 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4369802\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1037399\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (FDA approved in adult males); has also been used for nephrolithiasis and for management of primary bladder neck dysfunction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224801\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flomax may be confused with Flonase, Flovent, Foltx, Fosamax</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tamsulosin may be confused with tacrolimus, tamoxifen, terazosin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flomax [US, Canada, and multiple international markets] may be confused with Flomox brand name for cefcapene [Japan]; Volmax brand name for salbutamol [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flomax: Brand name for tamsulosin [US, Canada, and multiple international markets], but also the brand name for morniflumate [Italy]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224800\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Orthostatic hypotension </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, drowsiness, headache, insomnia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Loss of libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Ejaculation failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, pharyngitis, rhinitis, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening): Epistaxis, exfoliative dermatitis, hypersensitivity reaction, hypotension, intraoperative floppy iris syndrome, palpitation, priapism, syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224738\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, angioedema, rash, urticaria, pruritus, respiratory symptoms) to tamsulosin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with strong CYP3A4 inhibitors (including ketoconazole)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224723\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Angina: Discontinue if symptoms of angina occur or worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Floppy iris syndrome: Intraoperative floppy iris syndrome (IFIS) is characterized by a combination of flaccid iris that billows with intraoperative currents, progressive intraoperative miosis despite dilation, and potential iris prolapse. IFIS has been observed in cataract and glaucoma surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers, particularly with tamsulosin use (Abdel-Aziz, 2009); in some cases, patients had discontinued the alpha1-blocker 5 weeks to 9 months prior to the surgery.  The benefit of discontinuing alpha-blocker therapy prior to cataract or glaucoma surgery has not been established. IFIS may increase the risk of ocular complications during and after surgery.  May require modifications to surgical technique; instruct patients to inform ophthalmologist of current or previous alpha<sub>1</sub>-blocker use when considering eye surgery. Initiation of tamsulosin therapy in patients with planned cataract or glaucoma surgery is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. &ldquo;First-dose&rdquo; orthostatic hypotension may occur 4-8 hours after dosing; may be dose related. Patients should be cautioned about performing hazardous tasks, driving, or operating heavy machinery when starting new therapy or adjusting dosage upward.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Priapism has been associated with use (rarely).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfonamide allergy: Rarely, patients with a sulfa allergy have also developed an allergic reaction to tamsulosin; avoid use when previous reaction has been severe or life-threatening.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, tamsulosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostate cancer:  It is recommended to rule out prostatic carcinoma with screening before beginning therapy and then screen at regular intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Limitation of use: Not intended for use as an antihypertensive drug.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27641153\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tamsulosin has been well tolerated in pediatric patients during trials when used for management of nephrolithiasis and primary bladder neck dysfunction (Donohoe 2005; Mokhless 2012; Tasian 2014; Van Batavia 2010). Studies using tamsulosin for the management of elevated detrusor leak point pressure in pediatric patients (ages 2 to 16 years) with a known neurological disorder (eg, spina bifida) failed to show efficacy. In two pooled trials, adverse events occurring in &ge;5% of patients included urinary tract infection, vomiting, pyrexia, headache, nasopharyngitis, cough, pharyngitis, influenza, diarrhea, abdominal pain, and constipation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224788\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224728\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=100616&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tamsulosin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tamsulosin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: Alpha1-Blockers (Uroselective) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224751\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Fasting increases bioavailability by 30% and peak concentration 40% to 70%. Management: Administer 30 minutes after the same meal each day. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224729\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224740\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. For pregnant women with kidney stones, other treatments such as stents or ureteroscopy, are recommended if stone removal is needed (Preminger, 2007; Tan, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27641160\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, urinary symptoms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224722\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tamsulosin is an antagonist of alpha<sub>1A</sub>-adrenoreceptors in the prostate. Smooth muscle tone in the prostate is mediated by alpha<sub>1A</sub>-adrenoreceptors; blocking them leads to relaxation of smooth muscle in the bladder neck and prostate causing an improvement of urine flow and decreased symptoms of BPH. Approximately 75% of the alpha<sub>1</sub>-receptors in the prostate are of the alpha<sub>1A</sub> subtype.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224737\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Pharmacokinetics in pediatric patients (ages 2 to 16 years) were found to be similar to adult values (Tsuda 2010). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: &gt;90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 16 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 94% to 99%, primarily to alpha<sub>1</sub> acid glycoprotein (AAG) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (extensive) via CYP3A4 and 2D6; metabolites undergo extensive conjugation to glucuronide or sulfate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Fasting: 30% increase </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Steady-state: By the fifth day of once-daily dosing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Healthy volunteers: 9 to 13 hours; Target population: 14 to 15 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Fasting: 4 to 5 hours; With food: 6 to 7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (76%, &lt;10% as unchanged drug); feces (21%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224739\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Flomax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (100): $930.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Tamsulosin HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg (100): $421.36</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224742\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alfatam (UA);</li>\n      <li>Alna (AT, DE);</li>\n      <li>Bazetham (HR);</li>\n      <li>Bestflo (LK);</li>\n      <li>Comadex (EC);</li>\n      <li>Contiflo OD (ZW);</li>\n      <li>Eziflo (BD);</li>\n      <li>Flectone XL (GB);</li>\n      <li>Flomax (BB, NZ, TR);</li>\n      <li>Flomaxtra (AU, NZ);</li>\n      <li>Flomaxtra XL (GB);</li>\n      <li>Flosin (LV);</li>\n      <li>Flosure (LK);</li>\n      <li>Fokusin (LV, RO);</li>\n      <li>Harnal (CN, HK, JP, PH, QA);</li>\n      <li>Harnal D (ID);</li>\n      <li>Harnal OCAS (HK, ID, MY, PH, SG, TH, VN);</li>\n      <li>Harnalidge D (TW);</li>\n      <li>Harusin SR (KR);</li>\n      <li>Inreq (ES);</li>\n      <li>Josir (FR);</li>\n      <li>Kirnom (IE);</li>\n      <li>Libert (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lostam (EC);</li>\n      <li>Lutsnal (KR);</li>\n      <li>Maxflow (LK);</li>\n      <li>Maxrin (LK);</li>\n      <li>Mecir LP (FR);</li>\n      <li>Omexel LP (FR);</li>\n      <li>Omic (BE, LU);</li>\n      <li>Omix Ocas (CH);</li>\n      <li>Omnexel (IE);</li>\n      <li>Omnic (AE, AR, BH, BR, CL, CO, CZ, DE, DK, EE, ES, FI, GR, HR, HU, IL, IS, IT, JO, KW, LT, MT, NL, NO, PE, PL, PT, QA, RO, RU, SA, SI, SK);</li>\n      <li>Omnic OCAS (CY, IL, KW, LB, QA, SA);</li>\n      <li>Omnic Tocas (BG);</li>\n      <li>Omnik (UA);</li>\n      <li>Omsal (LV);</li>\n      <li>Petyme (GB);</li>\n      <li>Pimax (PH);</li>\n      <li>Pinexel PR (MT);</li>\n      <li>Promnix (IL);</li>\n      <li>Prozelax (PH);</li>\n      <li>Sasolin (BD);</li>\n      <li>Sebrane (ES);</li>\n      <li>Secotex (AR, BR, CL, CO, CR, DO, GT, HN, MX, NI, PA, PE, PY, SV, UY, VE);</li>\n      <li>Secotex OCAS (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Sulosin (KR);</li>\n      <li>Sultam (PH);</li>\n      <li>Tabphyn MR (GB);</li>\n      <li>Talusin (LB);</li>\n      <li>Tamlosin (TW);</li>\n      <li>Tamlosin SR (KR);</li>\n      <li>Tamnexyl (IE);</li>\n      <li>Tamodof (VN);</li>\n      <li>Tamsin (LK);</li>\n      <li>Tamsnal SR (KR);</li>\n      <li>Tamsol (BD);</li>\n      <li>Tamsu (IE);</li>\n      <li>Tamsulid (UA);</li>\n      <li>Tamsulin (IL, KW);</li>\n      <li>Tamsulo (KR);</li>\n      <li>Tamsulon (CR, DO, EC, GT, HN, NI, PA, SV);</li>\n      <li>Tamsustad (VN);</li>\n      <li>Tamunal (KR);</li>\n      <li>Tarunal (KR);</li>\n      <li>Urimax (IN);</li>\n      <li>Urnal (TW);</li>\n      <li>Uroflo (BD);</li>\n      <li>Uroflow (TH);</li>\n      <li>Urostad (LV);</li>\n      <li>Urotams SR (KR);</li>\n      <li>Xalgetz (VN);</li>\n      <li>Zotan (TW);</li>\n      <li>Zuantrip (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. <i>Curr Opin Ophthalmol</i>. 2009 Jan;20(1):37-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/19077827/pubmed\" target=\"_blank\" id=\"19077827\">19077827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. <i>J Urol</i>. 2005;173(1):212-216.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/15592078 /pubmed\" target=\"_blank\" id=\"15592078 \">15592078 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flomax (tamsulosin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; August 2014. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhless I, Zahran AR, Youssif M, Fahmy A. Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study.<i> J Pediatr Urol</i>. 2012;8(5):544-548. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/22099477 /pubmed\" target=\"_blank\" id=\"22099477 \">22099477 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Preminger GM, Tiselius HG, Assimos DG, et al, &quot;2007 Guideline For the Management of Ureteral Calculi,&quot; <i>J Urol</i>, 2007, 178(6):2418-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/17993340/pubmed\" target=\"_blank\" id=\"17993340\">17993340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan YK, Cha DY, and Gupta M, &quot;Management of Stones in Abnormal Situations,&quot; <i>Urol Clin North Am</i>, 2013, 40(1):79-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/23177637/pubmed\" target=\"_blank\" id=\"23177637\">23177637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tasian GE, Cost NG, Granberg CF, et al. Tamsulosin and spontaneous passage of ureteral stones in children: a multi-institutional cohort study. <i>J Urol</i>. 2014;192(2):506-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/24518765 /pubmed\" target=\"_blank\" id=\"24518765 \">24518765 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsuda Y, Tatami S, Yamamura N, et al. Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder. <i>Br J Clin Pharmacol</i>. 2010;70(1):88-101. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/20642551 /pubmed\" target=\"_blank\" id=\"20642551 \">20642551 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Batavia JP, Combs AJ, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy. <i>J Urol</i>. 2010;183(2):724-730.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tamsulosin-pediatric-drug-information/abstract-text/20022041 /pubmed\" target=\"_blank\" id=\"20022041 \">20022041 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 100616 Version 81.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224754\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F224755\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1037398\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1037429\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224732\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F224719\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1037434\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F4369802\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1037399\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F224801\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224800\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224738\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224723\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27641153\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F224788\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F224728\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F224751\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F224729\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224740\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F27641160\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224722\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F224737\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F224739\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224742\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/100616|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tamsulosin-drug-information\" class=\"drug drug_general\">Tamsulosin: Drug information</a></li><li><a href=\"topic.htm?path=tamsulosin-patient-drug-information\" class=\"drug drug_patient\">Tamsulosin: Patient drug information</a></li></ul></div></div>","javascript":null}